Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$77.28 +3.8%	$35.28	$4.77 ▼ $78.49	$5.84B	0.56	654,159 shs	1.38 million shs
AXSM Axsome Therapeutics	$118.51 +1.2%	$106.07	$75.56 ▼ $139.13	$5.91B	0.51	772,469 shs	727,981 shs
NUVL Nuvalent	$76.08 +3.3%	$78.60	$55.53 ▼ $113.51	$5.49B	1.3	538,853 shs	407,091 shs
SPRY ARS Pharmaceuticals	$13.50 -9.2%	$16.84	$10.00 ▼ $18.90	$1.33B	0.9	1.56 million shs	3.13 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+3.53%	+7.00%	+644.30%	+1,212.70%	+544.42%
AXSM Axsome Therapeutics	+0.13%	+7.71%	+14.23%	+11.49%	+33.25%
NUVL Nuvalent	+0.56%	-4.10%	-8.71%	+0.22%	-10.90%
SPRY ARS Pharmaceuticals	+1.85%	+2.76%	-15.46%	-0.73%	+10.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.8119 of 5 stars	3.6	3.0	0.0	3.3	0.8	0.6
AXSM Axsome Therapeutics	4.7686 of 5 stars	4.5	1.0	4.5	3.7	4.2	0.6
NUVL Nuvalent	3.2169 of 5 stars	4.5	1.0	0.0	2.7	3.3	0.0
SPRY ARS Pharmaceuticals	2.674 of 5 stars	3.6	0.0	0.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	19.48% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	50.20% Upside
NUVL Nuvalent	3.08	Buy	$118.91	56.29% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	129.63% Upside

Current Analyst Ratings Breakdown

Latest SPRY, AXSM, NUVL, and ABVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00
7/23/2025	ABVX Abivax	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $101.00
7/23/2025	ABVX Abivax	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$71.00
7/23/2025	ABVX Abivax	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $95.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
AXSM Axsome Therapeutics	$495.03M	11.95	N/A	N/A	$1.46 per share	81.17
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	14.97	$0.01 per share	1,724.08	$1.95 per share	6.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.02	N/A	-49.88%	-283.22%	-33.06%	N/A
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A

Latest SPRY, AXSM, NUVL, and ABVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
AXSM Axsome Therapeutics	1.66	1.57	1.51
NUVL Nuvalent	N/A	13.57	13.57
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
AXSM Axsome Therapeutics	81.49%
NUVL Nuvalent	97.26%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
AXSM Axsome Therapeutics	22.30%
NUVL Nuvalent	10.20%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.55 million	N/A	Not Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

SPRY, AXSM, NUVL, and ABVX Headlines

Recent News About These Companies

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in Stock

August 22 at 8:42 AM | insidertrades.com

Aberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRY

August 21 at 4:18 AM | marketbeat.com

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19 at 2:58 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY FY2025 Earnings

August 19 at 2:33 AM | americanbankingnews.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19 at 2:55 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19 at 2:55 AM | marketbeat.com

William Blair Issues Optimistic Forecast for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

Earnings Outlook For ARS Pharmaceuticals

August 12, 2025 | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.

August 6, 2025 | marketbeat.com

XTX Topco Ltd Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

August 6, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, AXSM, NUVL, and ABVX Company Descriptions

Abivax NASDAQ:ABVX

$77.28 +2.85 (+3.83%)

Closing price 04:00 PM Eastern

Extended Trading

$77.76 +0.48 (+0.63%)

As of 07:15 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics NASDAQ:AXSM

$118.51 +1.37 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$118.47 -0.04 (-0.03%)

As of 06:02 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Nuvalent NASDAQ:NUVL

$76.08 +2.43 (+3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$76.08 0.00 (0.00%)

As of 05:25 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$13.50 -1.37 (-9.21%)

Closing price 04:00 PM Eastern

Extended Trading

$13.98 +0.48 (+3.56%)

As of 06:53 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time